PELTHOS THERAPEUTICS INC
PTHSNYSE AMERICANπ #4474 by market capEarnings Mar 17US Equity
$6.77βΌ $0.04 (β0.66%)
Market closed Β· at closeTrack PTHS
Get earnings, price moves & breaking news on Telegram
24hβΌ 0.7%
7dβΌ 7.1%
14dβΌ 28.9%
30dβΌ 60.4%
ytdβΌ 77.1%
1yβΌ 74.3%
π¦Market Cap
$27M
Small Cap
πRevenue Growth (YoY)
β
πGross Margin
78.6%
High
π΅FCF Margin
β
βοΈP/S Ratio
0.6x
Cheap
Otter Score
β
Insufficient data
Trading Snapshot
- Day Range
- $6.76 β $6.87
- 52-Week Range
- $6.02 β $32.51
- Volume (shares)
- 1,622
- Avg Volume (shares)
- β
- Shares Outstanding
- 3.9M
- Next Earnings
- 2027-03-17
Fundamentals Snapshot
- Annual Revenue
- $17M
- Last Q Revenue
- $15M
- P/E Ratio
- β
- P/S Ratio
- 0.6x
- EPS (TTM)
- $-21.82
- Dividend Yield
- β
- Dilution (1yr)
- +429.3%
PELTHOS THERAPEUTICS INC
PTHSFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$17M
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnβt profitable yet.
β$32Mβ² +328.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
β$23Mβ² +291.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerβs slice.
3.2Mβ² +429.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
β$17MβΌ β$15M YoY
About PELTHOS THERAPEUTICS INC
Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.
π¦¦
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
πQualityβ
β
β
β
β
βοΈValuationβ
β
β
β
β
π§Dilutionβ
β
β
β
β
Overall Score
Insufficient data
β/100
Analyst Ratings
βConsensus
Buy
13 analysts
Strong Buy3
Buy9
Hold1
Sell0
Strong Sell0
Ratings as of Nov 2026
Latest News & Updates
News unavailable.